OHSU's Knight Cancer Institute
The Knight Cancer Institute at OHSU is an international leader in cancer research and precision treatment. Our institute’s director, Brian Druker, M.D., helped usher in the era of precision cancer medicine with research that led to the breakthrough drug Gleevec®. The Knight Cancer Institute is the only National Cancer Institute (NCI)-designated Cancer Center between Sacramento and Seattle, an honor earned only by the top cancer centers. It is also the headquarters for the NCI’s SWOG collaborative, a cancer research cooperative group that designs and conducts multidisciplinary clinical trials.